Ardelyx Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx or view top-rated stocks.

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ardelyx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Ardelyx.

Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The biopharmaceutical company earned $6.58 million during the quarter, compared to analysts' expectations of $1.10 million. Ardelyx had a negative trailing twelve-month return on equity of 78.63% and a negative net margin of 812.17%.
View Ardelyx's earnings history.

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX shares have increased by 21.7% and is now trading at $7.28.
View which stocks have been most impacted by COVID-19.

3 analysts have issued 12-month price targets for Ardelyx's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Ardelyx's share price to reach $14.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Ardelyx or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ardelyx include Taro Pharmaceutical Industries (TARO), Dicerna Pharmaceuticals (DRNA), Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), IGM Biosciences (IGMS), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Prestige Consumer Healthcare (PBH), MorphoSys (MOR), Axsome Therapeutics (AXSM), FibroGen (FGEN), OPKO Health (OPK), ALX Oncology (ALXO) and Morphic (MORF).
View all of ARDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (6.16%), BlackRock Inc. (6.06%), Rock Springs Capital Management LP (5.24%), 683 Capital Management LLC (2.84%), Price T Rowe Associates Inc. MD (2.50%) and Thrivent Financial for Lutherans (2.47%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, BNP Paribas Arbitrage SA, Morgan Stanley, Ikarian Capital LLC, RA Capital Management L.P., Silverarc Capital Management LLC, and State of Wisconsin Investment Board. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx or view top insider-selling stocks.

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Prudential Financial Inc., 683 Capital Management LLC, Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, Janus Henderson Group PLC, Citigroup Inc., and Letko Brosseau & Associates Inc..
View insider buying and selling activity for Ardelyx or or view top insider-buying stocks.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $7.28.

Ardelyx has a market capitalization of $718.60 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94,310,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

Ardelyx employs 129 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]